Unlock instant, AI-driven research and patent intelligence for your innovation.
Rivaroxaban tablet pharmaceutical composition
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of rivaroxaban and composition, applied in the field of medicine, capable of solving problems such as insufficient friability performance
Active Publication Date: 2017-05-17
HANGZHOU ZHUYANGXIN PHARMA
View PDF9 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, the present inventors have found that the friability properties of the tablets obtained using the prior art methods are not sufficient, which will seriously affect the ability of the tablets to be further coated with a film coating.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0075] Embodiment 1: Preparation of rivaroxaban tablet
[0076] Prescription composition (mg / tablet):
[0077] Chip:
[0078] Rivaroxaban (micronized) 20.0mg
[0079] Microcrystalline Cellulose 35.0mg
[0080] Lactose monohydrate 22.9mg
[0081] Croscarmellose (Ac-Di- FMC) 3.0mg
[0082] Hydroxypropyl methylcellulose (5cp) 3.0mg
[0083] Sodium Lauryl Sulfate 0.5mg
[0084] Magnesium stearate 0.6mg;
[0085] Coating:
[0086] Hydroxypropyl methylcellulose (15cp) 1.5mg
[0087] Polyethylene glycol with a molecular weight of 3350 0.5mg
[0088] Titanium dioxide 0.5 mg;
[0089] Total 87.5mg.
[0090]Preparation method: Dissolve hydroxypropyl methylcellulose and sodium lauryl sulfate in water. Micronized rivaroxaban is suspended in this solution. The suspension thus prepared is sprayed in the fluidized bed granulation stage as a wet granulation liquid onto a mixed powder material in a fluidized state consisting of microcrystalline cellulose, lactose monohydrate ...
Embodiment 2
[0091] Embodiment 2: Preparation of rivaroxaban tablet
[0092] Prescription composition (mg / tablet):
[0093] Chip:
[0094] Rivaroxaban (micronized) 5mg
[0095] Microcrystalline Cellulose 40mg
[0096] Lactose monohydrate 33.9mg
[0097] Croscarmellose (Ac-Di- FMC) 3mg
[0098] Hydroxypropyl methylcellulose (3cp) 2mg
[0099] Sodium Lauryl Sulfate 0.5mg
[0100] Magnesium stearate 0.6mg;
[0101] Coating:
[0102] Hydroxypropyl methylcellulose (15cp) 1.5mg
[0103] Polyethylene glycol with a molecular weight of 400 0.5 mg
[0104] Iron oxide yellow 0.1mg
[0105] Titanium dioxide 0.4mg;
[0106] Total 87.5mg.
[0107] Preparation method: carry out according to the preparation method of embodiment 1.
[0109] Prescription and preparation method are with reference to embodiment 1, and difference is only that the croscarmellose wherein is replaced with the croscarmellose sodium of equal amount.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Property
Measurement
Unit
particle size
aaaaa
aaaaa
hardness
aaaaa
aaaaa
diameter
aaaaa
aaaaa
Login to View More
Abstract
The invention belongs to the technical field of medicines, relates to a rivaroxaban troche pharmaceutical composition, and particularly relates to a pharmaceutical composition in form of a troche. The pharmaceutical composition includes rivaroxaban, a diluent, a disintegrant, an adhesive, a wetting agent and a lubricant. Each troche comprises 1-100mg of rivaroxaban. The troche can be further coated, for example, a film coated troche. The troche provided by the invention has the advantages described in specification. The rivaroxaban troche pharmaceutical composition has excellent dissolving-out performance, stability and other preparation performances.
Description
technical field [0001] The invention belongs to the technical field of medicine, and relates to a composition of anticoagulant drugs, in particular to a pharmaceutical composition of FXa inhibitor rivaroxaban, especially a tablet thereof, and to a preparation method of the pharmaceutical composition. Background technique [0002] Rivaroxaban was first described in WO01 / 47919, which has the following structure [0003] [0004] Molecular formula C 19 h 18 ClN 3 o 5 S, molecular weight 435.89, English name rivaroxaban, R&D code BAY5927939, trade name Xarelto, CAS366789-02-8, domestic drug name Xarelto, Chinese chemical name 5-chloro-N-({(5S)-2-oxo Substitute-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene carboxamide, English chemical name is 5 -Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide. Clinically used rivaroxaban is a pure (S)-enantiomer, which is an odorless, non-hygroscopic,...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.